Short Communication: Focal Encephalitis Related to Viral Escape and Resistance Emergence in Cerebrospinal Fluid in a Patient on Lopinavir/Ritonavir Monotherapy with Plasma HIV-1 RNA Suppression
Open Access
- 1 October 2014
- journal article
- case report
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 30 (10), 984-987
- https://doi.org/10.1089/aid.2014.0014
Abstract
Monotherapy with boosted protease inhibitors has emerged as an antiretroviral therapy simplification alternative for selected patients, endorsed by the results of some randomized clinical trials. However, there are some concerns about the efficacy of such a strategy in achieving successful viral suppression in those anatomic compartments or reservoirs in which antiretroviral drug penetration is lower, such as the central nervous system (CNS). Several studies have demonstrated better neurocognitive performance in patients receiving antiretroviral drugs with better cerebrospinal fluid (CSF) penetration. Nevertheless, cases of CSF viral escape accompanied by moderate or severe neurological symptoms have been reported with both standard triple therapy and boosted protease inhibitor (PI) monotherapy, and it is not well established whether ritonavir-boosted protease inhibitor (PI/r) monotherapy is associated with a higher risk of symptomatic CSF viral escape or not. Herein, we present a case of viral rebound and resistance emergence exclusively in CSF associated with an unusual clinical manifestation of focal encephalitis in a patient with plasma HIV-1 RNA suppression while receiving lopinavir/ritonavir monotherapy. Clinical resolution and CSF viral suppression were observed after switching to a genotype-guided combined antiretroviral regimen with good CSF penetration.Keywords
This publication has 24 references indexed in Scilit:
- Virological Efficacy in Cerebrospinal Fluid and Neurocognitive Status in Patients with Long-Term Monotherapy Based on Lopinavir/Ritonavir: An Exploratory StudyPLOS ONE, 2013
- Neurocognitive Impairment in Patients Treated with Protease Inhibitor Monotherapy or Triple Drug Antiretroviral TherapyPLOS ONE, 2013
- Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meetingAIDS Research and Therapy, 2013
- Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral loadAIDS, 2012
- Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohortAIDS, 2011
- Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136AIDS, 2010
- Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadirAIDS, 2010
- Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIVAIDS, 2008
- Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous SystemArchives of Neurology, 2008
- Updated research nosology for HIV-associated neurocognitive disordersNeurology, 2007